Stephen Holding

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3409621/publications.pdf

Version: 2024-02-01

430874 434195 48 972 18 31 citations h-index g-index papers 48 48 48 808 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Ibrutinib does not reverse disease- and treatment-related hypogammaglobulinaemia associated with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2021, 62, 1786-1789.	1.3	2
2	Challenges and opportunities from the revised international consensus on ANCA testing. Annals of Clinical Biochemistry, 2019, 56, 4-6.	1.6	2
3	Do anti-smooth muscle antibodies predict development of autoimmune hepatitis in patients with normal liver function? – A retrospective cohort review. Autoimmunity Reviews, 2016, 15, 668-672.	5.8	8
4	Current screening approaches for antibody deficiency. Current Opinion in Allergy and Clinical Immunology, 2015, 15, 547-555.	2.3	20
5	Incidence of PR3- and MPO-ANCA autoantibody specificity changes in ANCA-associated vasculitis. Annals of Clinical Biochemistry, 2015, 52, 297-301.	1.6	5
6	Using calculated globulin fraction to reduce diagnostic delay in primary and secondary hypogammaglobulinaemias: results of a demonstration project. Annals of Clinical Biochemistry, 2015, 52, 319-326.	1.6	30
7	Iron Age or New Age: Ironing out the Diagnosis of Anaemia of Inflammation from Iron Deficiency Anaemia. Blood, 2015, 126, 3354-3354.	1.4	1
8	Calculated globulin (CG) as a screening test for antibody deficiency. Clinical and Experimental Immunology, 2014, 177, 671-678.	2.6	55
9	Immediate hypersensitivity to chlorhexidine is increasingly recognised in the United Kingdom. Allergologia Et Immunopathologia, 2014, 42, 44-49.	1.7	58
10	Clinical evaluation of the BioPlex 2200 Celiac IgA and IgG Kits â€" A novel multiplex screen incorporating an integral check for IgA deficiency. Journal of Immunological Methods, 2014, 405, 29-34.	1.4	16
11	Introduction of first trimester combined test increases uptake of Down's syndrome screening. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 159, 95-98.	1.1	5
12	Direct access midwifery booking for prenatal care and its role in Down syndrome screening. Prenatal Diagnosis, 2011, 31, 985-989.	2.3	0
13	Use of serum free light chain analysis and urine protein electrophoresis for detection of monoclonal gammopathies. Clinical Chemistry and Laboratory Medicine, 2011, 49, 83-8.	2.3	22
14	Reduction in Down's Syndrome Screening Acceptance is Predominantly Observed in Women Aged 25–35 Years. Women's Health, 2010, 6, 525-529.	1.5	7
15	A randomised controlled trial of placental cord drainage to reduce feto-maternal transfusion. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2010, 149, 27-30.	1.1	5
16	Do ribosomopathies explain some cases of common variable immunodeficiency?. Clinical and Experimental Immunology, 2010, 163, 96-103.	2.6	27
17	Antigliadin antibody testing for coeliac disease in children under 3 years of age is unhelpful. Journal of Clinical Pathology, 2009, 62, 766-767.	2.0	5
18	Incorrect use of ratios in commercial assay kit instructions. Annals of Clinical Biochemistry, 2009, 46, 262-263.	1.6	0

#	Article	IF	Citations
19	The influence of maternal opiate use in pregnancy on second trimester biochemical markers for Down syndrome. Prenatal Diagnosis, 2009, 29, 863-865.	2.3	2
20	More studies are needed to assess the performance of serum free light chain measurement for the diagnosis of Bâ€cell disorders in routine clinical practice – response to Vermeersch <i>etÂal</i> Journal of Haematology, 2008, 143, 145-146.	2.5	2
21	Maternal serum screening for Down syndrome: are women's perceptions changing?. BJOG: an International Journal of Obstetrics and Gynaecology, 2007, 114, 458-461.	2.3	17
22	Prevalence of Abnormal Serum Free Light Chain Ratio in Monoclonal Gammopathies at Presentation and Sensitivity for Bence Jones Proteinuria Blood, 2007, 110, 1495-1495.	1.4	1
23	Combination of Serum Free Light Chain Analysis with Capillary Zone Electrophoresis Improves Screening for Monoclonal Gammopathies Blood, 2007, 110, 1497-1497.	1.4	4
24	The effect of newly diagnosed hypothyroidism on serum sodium concentrations: a retrospective study. Clinical Endocrinology, 2006, 64, 598-599.	2.4	54
25	The LH/FSH ratio has little use in diagnosing polycystic ovarian syndrome. Annals of Clinical Biochemistry, 2006, 43, 217-219.	1.6	47
26	Orlistat Is as Beneficial as Metformin in the Treatment of Polycystic Ovarian Syndrome. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 729-733.	3.6	128
27	The Biological Variation of Sex Hormone-Binding Globulin in Type 2 Diabetes: Implications for sex hormone-binding globulin as a surrogate marker of insulin resistance. Diabetes Care, 2004, 27, 278-280.	8.6	31
28	The Biological Variation of Insulin Resistance in Polycystic Ovarian Syndrome. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1560-1562.	3.6	28
29	Current state of screening for Down's syndrome. Annals of Clinical Biochemistry, 2002, 39, 1-11.	1.6	6
30	The Biological Variation of Insulin Resistance in Polycystic Ovarian Syndrome. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1560-1562.	3.6	8
31	Use of computer terminals on wards to access emergency test results: a retrospective audit. BMJ: British Medical Journal, 2001, 322, 1101-1103.	2.3	59
32	Biochemical screening for Down syndrome: patients' perception of risk. International Journal of Gynecology and Obstetrics, 2000, 68, 215-218.	2.3	2
33	Letter. Response to: Wald, N.J. and Hackshaw, A.K. (1997). Combining ultrasound and biochemistry in first-trimester screening for Down's syndrome,Prenat. Diagn.,17, 821–829. Prenatal Diagnosis, 1998, 18, 511-515.	2.3	19
34	Nomograms to help inform women considering Down's syndrome screening. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1996, 69, 69-72.	1.1	3
35	COMBINING INHIBIN A WITH EXISTING SECOND-TRIMESTER MARKERS IN MATERNAL SERUM SCREENING FOR DOWN'S SYNDROME. Prenatal Diagnosis, 1996, 16, 1095-1100.	2.3	69
36	COMBINING INHIBIN A WITH EXISTING SECONDâ€TRIMESTER MARKERS IN MATERNAL SERUM SCREENING FOR DOWN'S SYNDROME. Prenatal Diagnosis, 1996, 16, 1095-1100.	2.3	2

#	Article	IF	CITATIONS
37	Maternal serum dimeric inhibin A in second-trimester Down's syndrome pregnancies. Prenatal Diagnosis, 1995, 15, 385-386.	2.3	51
38	Full blood count and second-trimester markers of Down's syndrome. Prenatal Diagnosis, 1995, 15, 982-984.	2.3	1
39	Maternal serum screening for Down's syndrome taking account of the result in a previous pregnancy. Prenatal Diagnosis, 1994, 14, 321-322.	2.3	32
40	Maternal serum inhibin levels in second-trimester down's syndrome pregnancies. Prenatal Diagnosis, 1994, 14, 387-390.	2.3	42
41	Taking account of vaginal bleeding in screening for Down's syndrome. BJOG: an International Journal of Obstetrics and Gynaecology, 1994, 101, 948-952.	2.3	17
42	Low maternal serum oestriol and chorionic gonadotropin in the prediction of adverse pregnancy outcome. Prenatal Diagnosis, 1993, 13, 223-225.	2.3	4
43	Pregnancy associated plasma protein A in Down's syndrome BMJ: British Medical Journal, 1992, 305, 425-425.	2.3	29
44	Nongaussian Distribution of Second-Trimester Results for Serum Free Estriol. Clinical Chemistry, 1992, 38, 2336-2337.	3.2	1
45	Low maternal serum human chorionic gonadotrophin and unconjugated oestriol in a triploidy pregnancy. Prenatal Diagnosis, 1992, 12, 545-547.	2.3	18
46	Estimations of gestational age and screening for Down's syndrome BMJ: British Medical Journal, 1991, 302, 965-965.	2.3	12
47	Biochemical screening for Down's syndrome BMJ: British Medical Journal, 1991, 302, 1275-1275.	2.3	6
48	Clinical experience with the triple test for Down's syndrome screening. Journal of Perinatal Medicine, 1991, 19, 151-154.	1.4	9